Abstract

C3 Glomerulopathy (C3G) represents a spectrum of rare and severe kidney disorders characterized by the predominant deposition of complement component 3 (C3) within the glomeruli. This pathological process ultimately culminates in progressive renal dysfunction, often culminating in end-stage renal disease (ESRD). Recent and significant advancements in understanding the intricate pathogenesis of C3G, particularly concerning the dysregulation of the alternative complement pathway, have paved the way for the development and clinical application of novel, targeted therapeutic interventions. This comprehensive review meticulously delves into the complex pathophysiology, the heterogeneous array of clinical manifestations, contemporary diagnostic approaches, and evolving management strategies pertinent to C3G. A particular emphasis is placed on the transformative role of complement inhibition therapies, including the recently approved pegcetacoplan (Empaveli), a C3 inhibitor, which represents a significant milestone in targeted treatment. The report also thoroughly discusses the profound implications of these emerging treatments on long-term patient outcomes, critically evaluates current challenges, and outlines crucial directions for future research aimed at further refining diagnostic precision and therapeutic efficacy in C3G.

1. Introduction

C3 Glomerulopathy (C3G) encompasses a group of exceedingly rare, yet profoundly debilitating, kidney diseases distinguished by an aberrant and disproportionate accumulation of complement component 3 (C3) within the glomerular structures. Historically, these conditions were often misclassified under the umbrella of membranoproliferative glomerulonephritis (MPGN) due to overlapping histopathological appearances on light microscopy. However, with advances in immunofluorescence and electron microscopy, it became evident that a distinct subgroup existed where C3 deposition predominated, with minimal or absent immunoglobulin (Ig) and C1q deposition, leading to the coining of the term C3G. This spectrum primarily includes two major subtypes: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), also known as membranoproliferative glomerulonephritis type II (MPGN II). While both share the hallmark of C3 predominance, they are differentiated by distinct ultrastructural findings on electron microscopy, reflecting subtle yet significant differences in the underlying pathomechanisms.

These conditions frequently lead to severe clinical presentations, including nephrotic syndrome, characterized by massive proteinuria, hypoalbuminemia, and edema; hematuria, which can be microscopic or macroscopic; and, critically, progressive renal insufficiency that often culminates in end-stage renal disease (ESRD), necessitating renal replacement therapy such as dialysis or kidney transplantation. The profound impact of C3G on patient quality of life and survival underscores the urgent need for a deeper understanding of its etiology and effective therapeutic strategies.

The genesis of C3G lies in the profound dysregulation of the complement system, an essential component of innate immunity. Specifically, the alternative complement pathway (AP) is implicated, leading to its uncontrolled and perpetual activation. This aberrant activity results in the continuous and excessive generation and deposition of C3 fragments within the glomerular basement membrane (GBM) and mesangium, triggering an inflammatory cascade that culminates in progressive kidney damage. The identification of specific genetic mutations in complement regulatory proteins and the presence of acquired autoantibodies targeting complement components have elucidated the complex interplay of factors driving this dysregulation, shifting the paradigm of understanding C3G from an idiopathic condition to a disorder rooted in specific complement pathway defects.

This comprehensive review aims to provide an in-depth, contemporary analysis of C3G, extending beyond a mere descriptive overview. It will systematically explore its intricate pathophysiology, detailing the molecular mechanisms underlying complement dysregulation. It will then meticulously describe the diverse range of clinical presentations, highlighting the diagnostic challenges posed by its heterogeneity. A thorough exposition of current diagnostic modalities, emphasizing the critical role of kidney biopsy and specialized complement testing, will follow. Finally, the review will comprehensively discuss evolving management strategies, with a particular focus on the revolutionary advancements in targeted complement inhibition therapies, such as pegcetacoplan, which represent a significant leap forward in the treatment landscape for patients afflicted with this challenging disease.

2. Pathophysiology

The complement system is a highly complex and tightly regulated network of more than 50 plasma and cell-surface proteins that constitutes a crucial component of the innate immune response. Its primary functions include directly lysing pathogens, opsonizing immune complexes and microbial surfaces for clearance, regulating immune cell function, and participating in inflammation. The complement system can be activated via three distinct pathways: the classical pathway (CP), initiated by antibody-antigen complexes or C-reactive protein; the lectin pathway (LP), activated by mannose-binding lectin (MBL) binding to microbial carbohydrates; and the alternative pathway (AP), which is constitutively active at a low level and amplifies signals from the other two pathways, or can be directly activated by certain microbial surfaces and aberrant host surfaces. All three pathways converge at the level of C3, leading to the formation of C3 convertases, which cleave C3 into C3a (an anaphylatoxin) and C3b. C3b then covalently binds to surfaces, facilitating further activation and the formation of C5 convertases, ultimately leading to the generation of the membrane attack complex (MAC, C5b-9), responsible for direct cell lysis.

In C3 Glomerulopathy, the fundamental defect lies in the profound and often uncontrolled dysregulation of the alternative complement pathway. This aberrant activation leads to the continuous, excessive breakdown of C3 and the subsequent formation and stabilization of alternative pathway C3 convertases (C3bBb). Under normal physiological conditions, the AP is tightly regulated by a delicate balance of activating and inhibitory proteins to prevent indiscriminate host tissue damage. Key regulatory proteins include Factor H (CFH), Factor I (CFI), and Membrane Cofactor Protein (MCP, CD46), which inhibit the AP, and Properdin, which stabilizes the AP C3 convertase.

2.1 Core Components and Regulation of the Alternative Pathway

To fully appreciate the dysregulation in C3G, an understanding of the AP components is essential:

• C3: The central component, cleaved by C3 convertases into C3a and C3b. C3b serves as a platform for further activation.
• Factor B (CFB): Binds to C3b to form C3bB, which is then cleaved by Factor D.
• Factor D (CFD): A serine protease that cleaves Factor B when it is bound to C3b, generating C3bBb, the active alternative pathway C3 convertase. Factor D exists in plasma as its active form.
• Properdin (CFP): The only positive soluble regulator of the complement system. It stabilizes the C3bBb complex, extending its half-life and amplifying AP activation.
• Factor H (CFH): A crucial soluble negative regulator. It acts as a cofactor for Factor I-mediated cleavage of C3b (inactivating C3b to iC3b) and accelerates the decay of C3bBb. CFH also provides direct protection to host cells by binding to specific surface carbohydrates, distinguishing self from non-self.
• Factor I (CFI): A serine protease that, in conjunction with cofactors like Factor H, MCP, and C4bp, cleaves C3b into iC3b, thereby inactivating it and preventing convertase formation.
• Membrane Cofactor Protein (MCP/CD46): A cell-surface regulatory protein that acts as a cofactor for Factor I-mediated inactivation of C3b (and C4b) on host cell surfaces, protecting them from complement attack.

2.2 Mechanisms of Alternative Pathway Dysregulation in C3G

The uncontrolled AP activation in C3G primarily stems from either genetic mutations in complement regulatory proteins or the presence of acquired autoantibodies that interfere with normal complement function. This relentless activation leads to an overwhelming deposition of C3 fragments, such as C3b, iC3b, C3dg, and C3d, within the glomeruli. These fragments are highly inflammatory and chemotactic, recruiting immune cells and initiating a vicious cycle of inflammation and tissue damage, ultimately leading to glomerular injury and fibrosis.

2.2.1 Genetic Factors

Genetic predispositions play a significant role in the pathogenesis of C3G. Mutations or polymorphisms in genes encoding complement proteins can lead to either a loss of crucial regulatory function or an increase in activating potential. Key genes implicated include:

• Complement Factor H (CFH): Mutations in CFH are among the most common genetic aberrations found in C3G. A dysfunctional CFH protein fails to adequately regulate the alternative pathway, leading to unchecked C3b accumulation and convertase formation. Specific mutations can impair CFH’s ability to bind to C3b, serve as a cofactor for Factor I, or detach C3bBb, resulting in relentless AP activation. Deficiencies or mutations in CFH are also associated with atypical hemolytic uremic syndrome (aHUS), highlighting the overlap in complement-mediated diseases.
• Complement Factor I (CFI): Deficiencies or mutations in CFI impair its ability to cleave C3b (and C4b), leading to an accumulation of active C3b and thus enhanced AP activation. Since CFI requires cofactors, issues with these cofactors (like CFH or MCP) can indirectly mimic CFI deficiency.
• Membrane Cofactor Protein (MCP/CD46): Mutations in MCP compromise its cofactor activity for Factor I on cell surfaces. While less commonly associated with isolated C3G than CFH or CFI, MCP mutations contribute to a broader spectrum of complement dysregulation, including aHUS.
• Complement Factor B (CFB) and Complement Factor D (CFD): Gain-of-function mutations in CFB or CFD can lead to increased activity of these pro-enzymes, favoring increased C3 convertase formation. Although less frequent, these mutations tip the balance towards activation.
• C3 (C3): Mutations within the C3 gene itself can result in a C3 protein that is abnormally resistant to inactivation by Factor I and Factor H, effectively behaving like a gain-of-function mutation or creating a C3 molecule that is highly prone to convertase formation. This is a direct pathway to enhanced C3 breakdown and deposition.
• Properdin (CFP): As a positive regulator, deficiency of Properdin can paradoxically lead to dysregulation, as it may impair the orderly formation and stabilization of AP convertases on protective surfaces, shifting activation towards unprotected areas. Conversely, mutations leading to overactive Properdin could also contribute.
• Thrombomodulin (THBD): This endothelial cell surface protein serves as a cofactor for Factor I. Mutations in THBD can therefore impair C3b inactivation, contributing to complement dysregulation, similar to MCP.

2.2.2 Acquired Factors: Autoantibodies

In addition to genetic predispositions, a significant proportion of C3G cases involve acquired autoantibodies that directly interfere with complement regulation. These autoantibodies are often potent drivers of AP dysregulation:

• C3 Nephritic Factor (C3Nef): This is perhaps the most well-known acquired factor in C3G, particularly prevalent in DDD. C3Nef is an autoantibody (typically IgG, but sometimes IgM or IgA) that binds to and stabilizes the alternative pathway C3 convertase (C3bBb) and, less commonly, the classical pathway C3 convertase (C4b2a). By preventing the normal decay-accelerating activity of Factor H and other regulators, C3Nef prolongs the half-life of these convertases, leading to persistent and uncontrolled C3 cleavage and subsequent deposition. C3Nef can be detected in up to 60-80% of DDD patients and a variable percentage (10-40%) of C3GN patients.
• Autoantibodies against Factor H (anti-CFH antibodies): These antibodies directly neutralize the regulatory function of Factor H, preventing it from inhibiting C3 convertase activity or acting as a cofactor for Factor I. This leads to profound AP dysregulation, often presenting with severe forms of C3G and sometimes overlapping with aHUS. They are particularly common in pediatric C3G.
• Autoantibodies against Factor B (anti-CFB antibodies): Less common than anti-CFH antibodies, these autoantibodies can theoretically stabilize or enhance the activity of Factor B, promoting C3 convertase formation.
• Autoantibodies against Factor I (anti-CFI antibodies): These rare antibodies may inhibit Factor I’s ability to cleave C3b, leading to its accumulation.

2.3 Pathological Consequences and Subtype Differentiation

The continuous, unchecked activation of the alternative pathway leads to chronic inflammation and cellular proliferation within the glomeruli. The excessive C3 fragment deposition triggers an inflammatory response, leading to recruitment of inflammatory cells, activation of resident glomerular cells, and increased production of extracellular matrix components. This ultimately results in glomerular scarring (sclerosis) and functional impairment.

While both C3GN and DDD share the commonality of predominant C3 deposition, their distinction lies in the ultrastructural appearance of these deposits on electron microscopy (EM), which offers crucial insights into subtle differences in pathogenesis and sometimes prognosis:

• Dense Deposit Disease (DDD): Characterized by highly osmiophilic, electron-dense, ribbon-like deposits within the glomerular basement membrane (GBM) itself. These deposits appear as continuous, irregular, and often electron-dense bands, typically replacing the lamina densa of the GBM. This distinct morphology is thought to result from the in situ formation of C3 and complement components within the GBM, leading to its transformation. The deposits are so dense that they often obscure the normal fibrillar structure of the GBM. DDD is strongly associated with C3Nef and often presents with persistent hypocomplementemia.
• C3 Glomerulonephritis (C3GN): Characterized by less organized, discrete electron-dense deposits that are primarily found in the mesangium, subendothelial space (between the endothelium and the GBM), and occasionally in the subepithelial space (between the podocytes and the GBM). Unlike DDD, the GBM structure generally remains intact, although it may be thickened or show areas of lucency. The deposits in C3GN are variable in size and shape and lack the highly organized, ribbon-like appearance seen in DDD. C3GN is more heterogeneous in its underlying complement abnormalities, encompassing a wider range of genetic mutations and autoantibodies, and the degree of hypocomplementemia can be more variable.

Despite these ultrastructural differences, both conditions ultimately lead to similar clinical consequences of progressive renal injury, highlighting the central role of C3 dysregulation in their pathophysiology.

3. Clinical Manifestations

The clinical presentation of C3 Glomerulopathy is remarkably heterogeneous, exhibiting a wide spectrum of signs and symptoms that can vary significantly based on age of onset, the specific underlying complement abnormality, and the extent of renal damage. Patients may present with subtle, often asymptomatic findings, or with severe, rapidly progressive forms of kidney disease. This variability poses considerable challenges for timely diagnosis and appropriate management, necessitating a high index of suspicion from clinicians.

3.1 Spectrum of Presentation

The disease can manifest acutely, often mimicking other forms of glomerulonephritis, or insidiously, with slow, progressive deterioration of renal function over years. It affects individuals across all age groups, from young children to the elderly, though certain presentations are more common in specific age demographics. For instance, DDD often has an earlier onset in childhood or adolescence, while C3GN can present across the lifespan, including in adulthood.

3.2 Key Clinical Syndromes and Symptoms

The most common clinical syndromes associated with C3G include:

• Nephrotic Syndrome: This is a frequent presentation, particularly in patients with significant proteinuria. It is defined by the presence of:

  • Massive Proteinuria: Excretion of more than 3.5 grams of protein per 1.73 m² body surface area per day in adults (or >40 mg/hr/m² in children). Proteinuria in C3G is often non-selective and can be persistent and severe.
  • Hypoalbuminemia: Low serum albumin levels (<3.0 g/dL) resulting from hepatic underproduction and urinary loss.
  • Edema: Swelling, particularly in the lower extremities, periorbital region, and ascites, due to fluid retention secondary to low oncotic pressure and sodium retention.
  • Hyperlipidemia: Elevated cholesterol and triglyceride levels, often a compensatory hepatic response to hypoalbuminemia, increasing the risk of cardiovascular complications.
  • Patients with nephrotic syndrome are at increased risk for infections (due to loss of immunoglobulins) and thrombotic events (due to altered coagulation factors and volume depletion).

• Nephritic Syndrome (Acute Glomerulonephritis): This syndrome is characterized by:

  • Hematuria: Presence of blood in the urine, which can be microscopic (detected only on urinalysis) or macroscopic (gross, visible to the naked eye). Gross hematuria, often cola-colored or reddish-brown, may occur transiently, particularly following upper respiratory tract infections, resembling IgA nephropathy flares.
  • Hypertension: Elevated blood pressure, ranging from mild to severe, and often requiring antihypertensive medication. It is a common feature and can contribute to progressive kidney damage.
  • Oliguria and Acute Kidney Injury (AKI): Reduced urine output and a rapid decline in glomerular filtration rate (GFR), leading to an accumulation of waste products in the blood. This can signify rapidly progressive glomerulonephritis (RPGN), a severe manifestation requiring urgent intervention.

• Asymptomatic Urinary Abnormalities: In some cases, C3G may be discovered incidentally during routine medical examinations, revealing only persistent microscopic hematuria and/or proteinuria without overt symptoms or significant impairment of kidney function. Despite being asymptomatic initially, these patients are still at risk of disease progression.

• Recurrent Gross Hematuria: As mentioned, episodes of visible blood in the urine, often triggered by minor infections (pharyngitis, upper respiratory tract infections), are particularly noted in some patients, especially children.

• End-Stage Renal Disease (ESRD): A significant proportion of C3G patients, estimated at 30-50% within 10 years of diagnosis, will progress to ESRD, necessitating dialysis or kidney transplantation. The rate of progression to ESRD can vary widely, from rapid deterioration within months to a more indolent course over decades. Factors associated with faster progression include severe proteinuria, presence of crescents on biopsy, hypertension, and persistent hypocomplementemia.

3.3 Other Considerations

• Age of Onset: As noted, DDD often presents in childhood or young adulthood. C3GN can present at any age, but adult cases tend to have more variable clinical courses and complement profiles. Pediatric patients with C3G often have a higher incidence of C3Nef and anti-CFH autoantibodies.
• Systemic Associations: While C3G is primarily a kidney-limited disease, some patients, particularly those with underlying genetic defects in complement regulation, might have subtle systemic manifestations of complement dysregulation, such as drusen in the retina (a feature of age-related macular degeneration, which shares complement pathway involvement). However, these are not typical primary presenting features of C3G.

The heterogeneity of clinical presentations underscores the critical need for a comprehensive diagnostic workup that extends beyond routine kidney function tests and urinalysis, especially when confronted with unexplained persistent hypocomplementemia or an atypical glomerulonephritis presentation.

4. Diagnostic Approaches

Diagnosing C3 Glomerulopathy is a multi-faceted process that requires a meticulous integration of clinical assessment, comprehensive laboratory investigations, and, most critically, a definitive histopathological examination of kidney tissue. Given the rarity and heterogeneous nature of C3G, a high index of clinical suspicion is paramount, especially in patients presenting with unexplained glomerular disease, particularly those with persistent hypocomplementemia.

4.1 Clinical Suspicion and Initial Laboratory Investigations

Suspicion for C3G should arise in patients presenting with any of the typical glomerular disease syndromes: nephrotic syndrome, nephritic syndrome, recurrent gross hematuria, or persistent asymptomatic proteinuria/hematuria. The initial laboratory workup typically involves:

• Urinalysis: To assess for proteinuria (quantified by urine protein-to-creatinine ratio or 24-hour urine protein collection) and hematuria (microscopic or macroscopic, presence of red blood cell casts suggesting glomerular origin).
• Kidney Function Tests: Serum creatinine and blood urea nitrogen (BUN) to estimate glomerular filtration rate (eGFR) and assess the degree of renal impairment.
• Serum Albumin and Lipid Profile: To evaluate for nephrotic syndrome and its metabolic complications.

4.2 Specialized Complement Studies

Once a glomerular disease is suspected, a crucial step in differentiating C3G from other forms of glomerulonephritis involves a detailed assessment of the complement system. This is often the first laboratory clue to C3G:

• Serum Complement Levels:

  • C3: Classically, C3G is associated with persistently low serum C3 levels (hypocomplementemia). This is a direct consequence of the uncontrolled consumption and breakdown of C3 by the dysregulated alternative pathway.
  • C4: Typically, C4 levels are normal or near-normal in C3G. This distinction is critical, as low C4 (along with low C3) would suggest activation of the classical pathway, pointing towards diseases like lupus nephritis or cryoglobulinemic glomerulonephritis. The preservation of C4 levels in C3G underscores the predominant involvement of the alternative pathway, which bypasses C4.
  • CH50/AH50: Total hemolytic complement (CH50) assays measure the functional integrity of the entire classical complement pathway, while alternative pathway hemolytic activity (AH50) specifically assesses the functional integrity of the alternative pathway. In C3G, AH50 is often depressed, reflecting the underlying AP dysfunction, while CH50 might be low if C3 consumption is severe enough to impact overall pathway activity, or normal if the classical pathway itself is not activated.

• Autoantibody Screening: Detection of circulating autoantibodies that interfere with complement regulation is paramount and can inform prognosis and potential therapeutic strategies. These include:

  • C3 Nephritic Factor (C3Nef): An autoantibody that stabilizes the alternative pathway C3 convertase. Its presence strongly suggests C3G, particularly DDD. It can be detected using various assays, including a C3 convertase stabilization assay.
  • Autoantibodies to Factor H (anti-CFH antibodies): These antibodies neutralize Factor H’s regulatory function and are particularly common in pediatric C3G. Their presence indicates a significant risk of severe disease and recurrence post-transplant.
  • Autoantibodies to Factor B and Factor I: Less common but can also contribute to complement dysregulation.

4.3 Kidney Biopsy: The Definitive Diagnostic Tool

A definitive diagnosis of C3G, and its subclassification into C3GN or DDD, is established solely through a kidney biopsy. This procedure allows for a comprehensive histopathological examination using three critical techniques:

4.3.1 Light Microscopy (LM)

LM findings in C3G are often non-specific and can mimic various forms of glomerulonephritis. Common patterns include:

• Mesangial Proliferative Glomerulonephritis: Characterized by an increase in mesangial cells and matrix.
• Endocapillary Proliferative Glomerulonephritis: Involving proliferation of cells within the glomerular capillaries, often leading to capillary lumen occlusion. This can be diffuse or focal.
• Membranoproliferative Pattern: Characterized by mesangial interposition and often double-contour formation of the glomerular basement membrane (GBM), a common finding in both C3GN and DDD, hence the historical confusion with other MPGN types.
• Crescentic Glomerulonephritis: In severe, rapidly progressive cases, formation of crescents (extracapillary proliferation of parietal epithelial cells and macrophages) may be observed, indicating severe glomerular injury and a poor prognosis.
• Glomerulosclerosis: Focal or global scarring of glomeruli, reflecting chronic damage.

It is crucial to emphasize that while LM provides an initial assessment of the pattern and severity of injury, it cannot definitively diagnose C3G or differentiate its subtypes; this requires immunofluorescence and electron microscopy.

4.3.2 Immunofluorescence Microscopy (IF)

IF is the cornerstone for diagnosing C3G. It involves using fluorescently labeled antibodies to detect specific immune deposits within the glomeruli. The hallmark of C3G on IF is:

• Predominant C3 Deposition: Intense, bright staining for C3 in various glomerular locations (mesangium, capillary walls). The staining pattern can be granular or curvilinear, depending on the subtype and location of deposits.
• Absence or Minimal Immunoglobulin (Ig) Deposition: Crucially, there should be little to no significant staining for immunoglobulins (IgG, IgA, IgM) or other complement components like C1q. While trace or scattered Ig deposits might be present, the predominance of C3 is the defining diagnostic criterion. This distinguishes C3G from immune complex-mediated glomerulonephritis, where Ig and C1q staining would be prominent alongside C3.
• C4d Staining: C4d is a stable cleavage product of C4, a component of the classical and lectin pathways. In C3G, C4d staining is typically absent or minimal, further supporting the primary involvement of the alternative pathway.

4.3.3 Electron Microscopy (EM)

EM provides ultrastructural detail, allowing for the definitive subclassification of C3G into DDD or C3GN. This distinction is vital as it reflects fundamental differences in the nature and location of the C3 deposits, offering insights into pathogenesis and potentially prognosis:

• Dense Deposit Disease (DDD): The diagnostic feature of DDD is the presence of extremely electron-dense, highly organized, sausage- or ribbon-shaped deposits that are located within the glomerular basement membrane (GBM), effectively replacing the lamina densa. These deposits are so electron-dense that they appear solid and opaque, often obscuring the normal fibrillar structure of the GBM. They can also be found to a lesser extent in the mesangium and Bowman’s capsule.
• C3 Glomerulonephritis (C3GN): In contrast to DDD, C3GN is characterized by electron-dense deposits that are primarily found in the mesangium, subendothelial space (between the endothelium and the GBM), and occasionally in the subepithelial space (between the podocytes and the GBM). These deposits are typically less organized, more discrete, and varied in size and shape compared to the ribbon-like deposits of DDD. The GBM architecture in C3GN generally remains intact, although it may be thickened, and lucent areas may surround the deposits.

4.4 Genetic Testing

Genetic testing for mutations in complement regulatory genes (e.g., CFH, CFI, C3, CFB, CFD, MCP, THBD) is increasingly becoming an integral part of the diagnostic workup for C3G. It is particularly recommended in:

• Cases with a familial history of kidney disease or complement-mediated disorders.
• Patients with very early onset disease (pediatric cases).
• Cases with atypical presentations or where the initial complement workup is inconclusive.
• Planning for kidney transplantation, as certain genetic mutations (e.g., in CFH) are associated with a higher risk of disease recurrence in the transplanted kidney.

Genetic testing can provide crucial insights into the specific etiological drivers of C3G in an individual patient, which can guide prognosis, inform family counseling, and potentially influence treatment decisions.

In summary, the diagnosis of C3G is a meticulous process, requiring a synergistic approach involving clinical suspicion, detailed complement serology, and critically, a kidney biopsy with comprehensive light microscopy, immunofluorescence demonstrating predominant C3, and electron microscopy for subclassification. Genetic testing further refines the understanding of the underlying pathogenesis in individual patients.

5. Management Strategies

The management of C3 Glomerulopathy is complex, primarily due to its rarity, variable clinical course, and the historical lack of highly effective targeted therapies. The approach is typically multifaceted, combining general supportive measures, conventional immunosuppression, and, increasingly, novel complement inhibition therapies. The overarching goals are to control symptoms, reduce proteinuria, stabilize renal function, prevent progression to ESRD, and minimize treatment-related side effects. The specific treatment plan is highly individualized, taking into account the patient’s age, disease severity, rate of progression, presence of specific complement abnormalities (e.g., autoantibodies, genetic mutations), and the C3G subtype (DDD vs. C3GN).

5.1 Supportive Therapies

Supportive care forms the cornerstone of C3G management for all patients, irrespective of the need for specific immunosuppressive or targeted therapies. These interventions aim to mitigate the consequences of kidney damage and control symptoms:

• Blood Pressure Control: Hypertension is common in C3G and significantly contributes to the progression of kidney disease. Aggressive blood pressure control is essential, typically targeting levels <130/80 mmHg or even lower, especially in the presence of proteinuria. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are the first-line agents. Beyond blood pressure reduction, ACEi/ARBs offer significant renoprotective benefits by reducing intraglomerular pressure and directly decreasing proteinuria. Regular monitoring of kidney function and serum potassium is crucial when initiating or titrating these medications.

• Proteinuria Reduction: Proteinuria is a key marker of glomerular injury and a strong predictor of progressive kidney disease. ACEi/ARBs are fundamental in reducing proteinuria. In some cases, higher doses of these agents, or their combination (if tolerated), may be used. Dietary protein restriction (e.g., 0.8 g/kg/day) may also be considered in patients with significant proteinuria, though this must be carefully managed to prevent malnutrition.

• Edema Management: Diuretics, such as loop diuretics (e.g., furosemide) or thiazide diuretics, are used to manage fluid overload and edema, particularly in patients with nephrotic syndrome. Dietary sodium restriction is also strongly recommended to enhance the efficacy of diuretics and control fluid retention.

• Lipid Management: Patients with nephrotic syndrome often develop hyperlipidemia, increasing their risk of cardiovascular disease. Statins are commonly prescribed to lower cholesterol levels. Dietary modifications focusing on reduced saturated and trans fats are also important.

• Infection Prophylaxis: Patients with nephrotic syndrome, and especially those on immunosuppressive or complement-inhibiting therapies, are at increased risk of infections. Vaccination against common encapsulated bacteria (e.g., Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b) is highly recommended, and antibiotics may be prescribed for specific indications. Monitoring for signs of infection is critical.

• Renal Replacement Therapy (RRT): For patients who progress to end-stage renal disease, RRT options include dialysis (hemodialysis or peritoneal dialysis) and kidney transplantation. Recurrence of C3G in the renal allograft is a significant concern, particularly in DDD (up to 90% recurrence rate) and in C3GN associated with specific genetic defects (e.g., CFH mutations) or autoantibodies (e.g., C3Nef, anti-CFH). Pre-transplant complement depletion strategies or post-transplant monitoring for recurrence and prompt intervention are often considered.

5.2 Immunosuppressive Therapies

The role of conventional immunosuppressive agents in C3G has been a subject of ongoing debate, largely due to a lack of robust evidence from large-scale, randomized controlled trials. Their use is often based on observational studies, expert opinion, and extrapolation from other glomerulonephritides. Immunosuppression is generally considered for patients with progressive disease, significant proteinuria, or acute manifestations like rapidly progressive glomerulonephritis (RPGN).

• Corticosteroids: High-dose corticosteroids (e.g., methylprednisolone pulses followed by oral prednisone) are often used in acute, severe presentations, such as RPGN or severe nephrotic syndrome, to rapidly suppress inflammation. Their long-term efficacy in preventing progression in C3G is variable, and the significant side effects associated with prolonged use (e.g., osteoporosis, diabetes, hypertension, infections) limit their sustained application. They are frequently used in combination with other immunosuppressants.

• Mycophenolate Mofetil (MMF): MMF (or mycophenolic acid) is a widely used immunosuppressant that inhibits lymphocyte proliferation. It has been used in C3G, often in combination with corticosteroids, based on its efficacy in other glomerular diseases. Some retrospective studies and case series suggest that MMF may help reduce proteinuria and stabilize kidney function, particularly in C3GN. However, its effectiveness in DDD is less clear. Side effects include gastrointestinal disturbances and increased risk of infection.

• Cyclophosphamide: A potent alkylating agent, cyclophosphamide is generally reserved for severe, rapidly progressive forms of C3G, particularly those with extensive crescent formation. Its use is limited by significant cumulative toxicity, including bone marrow suppression, gonadal toxicity, and increased risk of malignancy.

• Rituximab: A chimeric monoclonal antibody targeting the CD20 antigen on B lymphocytes, leading to B-cell depletion. While primarily used in autoimmune diseases like lupus nephritis or ANCA-associated vasculitis, rituximab has been explored in C3G, particularly in cases with circulating autoantibodies (e.g., C3Nef, anti-CFH antibodies), given that B cells are responsible for antibody production. Case reports and small series have shown variable success, with some patients achieving partial or complete remission of proteinuria and stabilization of kidney function. Its role is still evolving, but it represents a potential option for specific patient subsets, especially those with clearly identified autoantibodies.

• Eculizumab (C5 Inhibitor): Eculizumab, a monoclonal antibody that targets complement C5, preventing its cleavage into C5a and C5b and thus blocking MAC formation, has proven highly effective in atypical hemolytic uremic syndrome (aHUS). However, its efficacy in C3G is generally limited. This is because C3G is primarily driven by C3 dysregulation, occurring upstream of C5 activation. While C5 inhibition prevents MAC formation (which is relevant for cell lysis), it does not directly prevent the massive deposition of C3 fragments, which are the primary drivers of glomerular injury in C3G. Therefore, while it may alleviate some inflammatory components, it does not address the root cause of C3 deposition, making it less effective than C3-targeted therapies.

5.3 Complement Inhibition Therapies: A New Era

The most significant therapeutic advancement in C3G management has been the development of targeted complement inhibition therapies that specifically address the underlying dysregulation of the alternative pathway. These therapies represent a paradigm shift from broad immunosuppression to precise molecular intervention.

5.3.1 Pegcetacoplan (Empaveli)

Pegcetacoplan is a pegylated peptide that binds to C3 and C3b, effectively inhibiting complement activation at the C3 level, the central component of all three complement pathways. By blocking C3, it prevents the formation of C3 convertases and subsequent downstream complement activation, including C5 cleavage and MAC formation. This upstream inhibition is crucial for C3G, as it directly targets the source of pathological C3 deposition. Pegcetacoplan is administered subcutaneously.

• Mechanism of Action: Pegcetacoplan acts as a proximal complement inhibitor. It binds to C3 and its activated fragment, C3b, preventing their cleavage and subsequent amplification of the complement cascade. This effectively dampens the uncontrolled alternative pathway activity responsible for C3G, reducing C3 consumption and deposition in the glomeruli.

• Clinical Evidence: The VALIANT Study: The efficacy and safety of pegcetacoplan in C3G and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN, a related condition with complement involvement) were rigorously evaluated in the Phase 3 VALIANT study (NCT05067275). This was a randomized, double-blind, placebo-controlled study conducted globally.

  • Study Design: The VALIANT study enrolled patients aged 12 years and older with biopsy-proven C3G or primary IC-MPGN, who had persistent proteinuria despite optimized standard of care. Patients were randomized to receive either pegcetacoplan or placebo.
  • Key Endpoints: The primary endpoint was the percentage reduction in C3G Patient Reported Outcome (C3G-PRO) total score at week 26. Key secondary endpoints included percent reduction in 24-hour urine protein-to-creatinine ratio (UPCR) and stabilization of estimated glomerular filtration rate (eGFR).
  • Results: Preliminary data from the VALIANT study, presented at the 62nd European Renal Association Congress (June 2025), demonstrated highly encouraging results. Patients treated with pegcetacoplan showed a significant and clinically meaningful reduction in proteinuria compared to placebo. Specifically, the study reported a 68% reduction in proteinuria from baseline at 26 weeks, a substantial improvement over the placebo group. Furthermore, pegcetacoplan treatment led to the stabilization of kidney function (eGFR), preventing the decline observed in the placebo group over the study period. Long-term data at one year continued to show sustained efficacy.
  • Safety Profile: The safety profile of pegcetacoplan was generally consistent with previous studies. Common adverse events included injection site reactions, infections (predominantly upper respiratory tract infections), and headache. As with any broad complement inhibitor, the risk of serious encapsulated bacterial infections, particularly Neisseria meningitidis, is a concern, necessitating appropriate vaccinations and prophylactic antibiotics (e.g., penicillin) as per guidelines.

• FDA Approval: Based on these compelling results, the U.S. Food and Drug Administration (FDA) approved pegcetacoplan (Empaveli) in July 2025 as the first approved treatment specifically for patients aged 12 years and older with C3G and primary IC-MPGN. This approval marks a pivotal moment, offering a targeted therapeutic option where none previously existed.

5.3.2 Other Complement Inhibitors in Development

The success of pegcetacoplan has spurred further research into other complement pathway inhibitors for C3G and related complement-mediated kidney diseases:

• Iptacopan (LNP023): An oral, small molecule inhibitor of Factor B, a key component of the alternative pathway convertase. By inhibiting Factor B, iptacopan aims to prevent the formation of the AP C3 convertase upstream. Clinical trials are ongoing for various complement-mediated diseases, including C3G (e.g., APPEAR-C3G trial, NCT04558482). Its oral administration offers a convenience advantage.
• Danicopan (CRN02994): An oral, selective inhibitor of Factor D, another crucial enzyme in the alternative pathway. Factor D cleaves Factor B to form the active convertase. By inhibiting Factor D, danicopan aims to block AP activation. It is currently being investigated for C3G (e.g., NCT05047464) and other complement-mediated disorders.
• Recombinant Factor H/Factor H Concentrates: For patients with specific genetic deficiencies or dysfunctional Factor H, administration of recombinant Factor H or plasma-derived Factor H concentrates represents a logical replacement strategy. This approach aims to restore proper complement regulation. Research in this area is ongoing, particularly for Factor H-deficient aHUS and potentially specific C3G phenotypes.

The advent of these targeted therapies signifies a profound shift in the therapeutic landscape for C3G, moving towards precision medicine based on the underlying molecular pathology.

6. Implications of Complement Inhibition Therapies

The recent approval of pegcetacoplan (Empaveli) for C3 Glomerulopathy and primary IC-MPGN represents a landmark achievement in the field of nephrology and orphan diseases. This development carries profound implications for patient care, disease management paradigms, and future research directions.

6.1 A Paradigm Shift in Treatment

For decades, the management of C3G was largely limited to non-specific supportive care and conventional immunosuppressive agents, whose efficacy was often anecdotal, inconsistent, and associated with significant side effects. The approval of pegcetacoplan fundamentally changes this landscape by providing the first disease-specific, targeted therapy. By directly addressing the underlying complement dysregulation at the C3 level, complement inhibitors move beyond merely managing symptoms or broadly suppressing the immune system. They offer the potential to directly halt or significantly slow the progression of the disease by interrupting the pathogenic cascade at its root.

6.2 Improved Patient Outcomes

The observed reduction in proteinuria and stabilization of kidney function in the VALIANT study are incredibly encouraging. Proteinuria is a well-established surrogate marker for kidney disease progression, and its reduction often correlates with improved long-term renal survival. By preserving eGFR and mitigating protein loss, these therapies hold the promise of:

• Delaying or Preventing End-Stage Renal Disease (ESRD): A significant proportion of C3G patients progress to ESRD, necessitating lifelong dialysis or kidney transplantation. Targeted complement inhibition may significantly delay or even prevent this dire outcome, thereby reducing the immense personal, social, and economic burden associated with ESRD.
• Reducing Morbidity and Complications: Sustained reduction in proteinuria can alleviate symptoms like edema, improve nutritional status (by reversing hypoalbuminemia), and potentially reduce the risk of complications associated with nephrotic syndrome, such as infections and thrombotic events.
• Improving Quality of Life: Preventing or delaying ESRD and mitigating symptoms can dramatically improve the quality of life for patients, allowing them to lead more active and fulfilling lives free from the constraints of advanced kidney disease or intense immunosuppression.
• Potential for Recurrence Post-Transplant: While current data primarily focus on native kidney disease, the success of complement inhibition opens avenues for preventing or treating C3G recurrence in kidney transplant recipients, a major challenge, especially for DDD and certain C3GN phenotypes.

6.3 Challenges and Considerations

Despite the groundbreaking potential, the widespread implementation of complement inhibition therapies comes with several challenges and considerations:

• High Cost of Therapy: Novel biological therapies are inherently expensive. The high cost of pegcetacoplan will pose significant accessibility challenges, particularly in healthcare systems with limited resources. This necessitates careful cost-effectiveness analyses and equitable access strategies.
• Long-Term Safety and Efficacy Data: While initial clinical trials show promise, the long-term safety and efficacy of these drugs, particularly over many years, require further investigation. Extended follow-up studies and real-world data collection through patient registries are crucial to fully understand their impact on disease progression, side effect profiles, and overall patient outcomes.
• Infection Risk: Inhibition of the complement system, especially at a proximal level (C3), can increase susceptibility to infections, particularly against encapsulated bacteria like Neisseria meningitidis. Therefore, strict adherence to vaccination protocols (meningococcal serogroups ACWY and B, pneumococcal, H. influenzae) and potentially prophylactic antibiotics (e.g., penicillin) is imperative for all patients receiving these therapies.
• Patient Selection and Biomarkers of Response: While pegcetacoplan is approved for all C3G patients 12 and older, identifying which patients are most likely to respond optimally, or which specific complement abnormalities predict better response, remains an area of active research. The development of reliable biomarkers to monitor treatment response and guide therapy duration will be invaluable.
• Route of Administration and Adherence: Pegcetacoplan requires subcutaneous administration, which, while more convenient than intravenous infusions, still necessitates patient training and adherence, particularly for chronic treatment.
• Understanding Residual Damage: Complement inhibition aims to halt disease progression, but it may not reverse existing damage (e.g., severe glomerulosclerosis). The timing of intervention, perhaps earlier in the disease course, may be crucial for maximizing benefits.

In conclusion, complement inhibition therapies, spearheaded by pegcetacoplan, mark a transformative era in the management of C3G. They offer the unprecedented opportunity to alter the natural history of this devastating disease, moving towards a future where ESRD can be prevented or significantly delayed for many patients. However, vigilance regarding long-term safety, equitable access, and continued research will be essential to fully realize their potential.

7. Future Research Directions

While the recent advancements in complement inhibition therapies have revolutionized the management of C3 Glomerulopathy, significant gaps in knowledge remain, necessitating robust and collaborative future research efforts. These directions aim to refine diagnostic precision, optimize therapeutic strategies, and ultimately improve the long-term prognosis and quality of life for patients with C3G.

7.1 Elucidating Genetic and Molecular Mechanisms

Despite progress, a considerable proportion of C3G cases remain without an identifiable genetic mutation or specific autoantibody. Future research should focus on:

• Comprehensive Genetic Screening: Expanding genetic panels to identify novel candidate genes or rare variants that contribute to C3G pathogenesis. This includes exploring epigenetic modifications and non-coding RNA involvement.
• Functional Characterization of Variants: Moving beyond identifying mutations to understanding their precise functional impact on complement protein activity and regulation. This can involve in vitro and in vivo studies to determine pathogenicity.
• Biomarker Discovery: Identifying novel soluble and tissue-based biomarkers for early diagnosis, prediction of disease progression, and monitoring treatment response. This includes advanced complement activation products (e.g., C3adesArg, soluble C5b-9), specific autoantibody profiles, and omics-based approaches (proteomics, metabolomics) to identify unique disease signatures.
• Understanding Genotype-Phenotype Correlations: Establishing clearer correlations between specific genetic mutations or autoantibody profiles and clinical presentation, disease severity, and response to different therapies. This is crucial for personalized medicine approaches.

7.2 Optimizing Complement Inhibition Therapies

The approval of pegcetacoplan is a significant first step, but much remains to be learned about its optimal use and the potential of other targeted therapies:

• Large-Scale Randomized Controlled Trials (RCTs): While the VALIANT study was pivotal, further large-scale, multicenter RCTs are needed to compare the efficacy and safety of pegcetacoplan against conventional immunosuppression, and potentially against new complement inhibitors (e.g., Factor B/D inhibitors) as they emerge.
• Optimal Treatment Protocols: Determining the optimal duration of therapy, dosing regimens, and criteria for treatment withdrawal or tapering. Identifying patient subsets who might benefit from lower doses or intermittent therapy could reduce cost and side effects.
• Combination Therapies: Exploring the role of combining complement inhibitors with conventional immunosuppressants (e.g., corticosteroids, MMF) or other novel agents. This could potentially allow for lower doses of each drug, minimizing side effects while maximizing efficacy.
• Comparative Effectiveness Research: Studies comparing different complement inhibitors as they become available, evaluating their relative efficacy, safety, and cost-effectiveness in diverse patient populations.
• Real-World Evidence (RWE): Establishing robust patient registries and conducting observational studies to gather real-world data on long-term outcomes, safety profiles, and recurrence rates, especially in patients who were not eligible for clinical trials.

7.3 Pediatric C3G Research

Children with C3G often present with more severe disease and a higher burden of complement abnormalities. Dedicated research for this vulnerable population is crucial:

• Pediatric-Specific Trials: Conducting clinical trials specifically designed for pediatric patients to establish efficacy, safety, and optimal dosing for complement inhibitors in this age group.
• Growth and Development: Assessing the long-term impact of C3G and its treatments on growth, development, and quality of life in children.
• Transition of Care: Developing effective strategies for transitioning pediatric patients to adult care, ensuring continuity and appropriate management.

7.4 Recurrence Post-Kidney Transplantation

Recurrence of C3G in the renal allograft is a major challenge, especially for DDD and certain C3GN variants. Future research should focus on:

• Predictive Markers for Recurrence: Identifying pre-transplant biomarkers (e.g., specific complement factor levels, autoantibodies, genetic profiles) that reliably predict recurrence risk.
• Pre-emptive Strategies: Evaluating the efficacy of pre-transplant complement depletion or post-transplant prophylactic complement inhibition to prevent recurrence.
• Treatment of Recurrent Disease: Developing effective strategies for managing recurrent C3G in the allograft to preserve transplant function and longevity.

7.5 Patient-Reported Outcomes and Quality of Life

Beyond biochemical markers and renal function, understanding the patient’s perspective is critical. Research should focus on:

• Patient-Reported Outcomes (PROs): Integrating PROs into clinical trials and routine care to comprehensively assess the impact of disease and treatment on symptoms, functional status, and overall quality of life.
• Psychosocial Support: Exploring the need for and effectiveness of psychosocial support interventions for patients and families coping with a rare and chronic kidney disease.

7.6 Understanding Disease Mechanisms and Pathological Heterogeneity

Deepening the understanding of why specific complement defects lead to the distinct histological features of DDD versus C3GN is important:

• Cellular and Molecular Interactions: Investigating the role of glomerular cells (podocytes, endothelial cells, mesangial cells) and their interactions with complement components in promoting or ameliorating injury.
• Role of Immune Cells: Further characterizing the involvement of specific immune cells (e.g., macrophages, T cells) in the inflammatory response in C3G.

By pursuing these diverse research avenues, the scientific and medical community can continue to build upon the foundational advancements already made, leading to more precise diagnostics, more effective and personalized therapies, and ultimately, better lives for individuals affected by C3 Glomerulopathy.

8. Conclusion

C3 Glomerulopathy (C3G), encompassing C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), stands as a complex, rare, and often devastating spectrum of kidney disorders. Its pathogenesis is intricately linked to profound and uncontrolled dysregulation of the alternative complement pathway, leading to the pathological deposition of complement component 3 (C3) within the glomeruli. The clinical presentation is highly variable, ranging from insidious asymptomatic proteinuria to acute nephritic syndrome or rapidly progressive renal failure, frequently culminating in end-stage renal disease (ESRD), which places a significant burden on patients and healthcare systems.

The diagnostic process for C3G is demanding, relying on a meticulous integration of clinical suspicion, detailed complement serology (notably persistently low C3 with normal C4), and, critically, a comprehensive kidney biopsy. Immunofluorescence microscopy showing predominant C3 staining and electron microscopy providing the definitive subclassification into DDD (intramembranous dense deposits) or C3GN (mesangial and subendothelial/subepithelial deposits) are indispensable. Furthermore, genetic testing and autoantibody screening are increasingly important in elucidating the underlying etiology and informing prognosis.

For many years, management strategies for C3G were largely limited to supportive care and broad, often inconsistently effective, immunosuppressive therapies with considerable side effects. However, the landscape of C3G treatment has been profoundly transformed by recent advancements in targeted complement inhibition. The approval of pegcetacoplan (Empaveli), a C3 inhibitor, based on robust data from the Phase 3 VALIANT study demonstrating significant proteinuria reduction and stabilization of kidney function, marks a pivotal milestone. This targeted therapy offers the unprecedented opportunity to address the root cause of C3G by blocking aberrant complement activation upstream, potentially altering the natural history of the disease and delaying or preventing progression to ESRD.

While these novel therapies offer immense promise, comprehensive management of C3G necessitates a holistic and multidisciplinary approach. This includes diligent supportive care to manage symptoms and comorbidities, the judicious application of conventional immunosuppression in select cases, and the careful integration of targeted complement inhibition. Vigilant long-term monitoring is essential to assess treatment efficacy, manage potential side effects (particularly infection risk), and adapt therapeutic strategies as the disease evolves.

Looking ahead, ongoing research is paramount. Future endeavors must focus on deciphering the full spectrum of genetic and molecular mechanisms driving C3G, discovering novel biomarkers for early diagnosis and personalized treatment, optimizing existing complement inhibition therapies through larger trials and combination strategies, and developing new therapeutic modalities. Special attention is required for pediatric patients and strategies to prevent and manage disease recurrence post-kidney transplantation. By continuing to unravel the complexities of C3G, the medical community can further refine diagnostic precision and enhance therapeutic outcomes, ultimately improving the lives of individuals affected by this challenging rare kidney disorder.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. Apellis Pharmaceuticals, Inc. FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older. July 28, 2025. https://investors.apellis.com/news-releases/news-release-details/fda-approves-apellis-empavelir-pegcetacoplan-first-c3g-and

2. Gale DP, Bomback AS, Licht C, et al. Pegcetacoplan Treatment Appears to Halt Disease Progression in C3G and Primary (Idiopathic) IC-MPGN Patients: Results from the Phase 3 VALIANT Study. Presented at: 62nd European Renal Association Congress. June 04 – 07, 2025. Vienna, Austria. https://www.hcplive.com/view/pegcetacoplan-could-halt-disease-progression-in-c3-glomerulopathy-ic-mpgn-with-daniel-gale-phd-mb-bchir

3. C3 Glomerulopathy – GeneReviews® – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK1425/

4. C3 Glomerulopathy: Update on Pathogenesis and Treatment in: Kidney News Volume 13 Issue 4 (2021). https://www.kidneynews.org/view/journals/kidney-news/13/4/article-p39_17.xml

5. Complement 3 Glomerulopathy (C3G): Causes & Treatment. https://my.clevelandclinic.org/health/diseases/25074-c3g

6. FDA Approves Medication to Treat 2 Rare Diseases that Can Lead to Kidney Failure. https://content.govdelivery.com/accounts/USFDA/bulletins/3eb9762

7. Pegcetacoplan. https://en.wikipedia.org/wiki/Pegcetacoplan

8. Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN. https://investors.apellis.com/news-releases/news-release-details/apellis-and-sobi-announce-empavelir-pegcetacoplan-showed

9. Empaveli Approved for C3G and Primary IC-MPGN. https://www.medscape.com/viewarticle/empaveli-approved-c3g-and-primary-ic-mpgn-2025a1000k5g

10. Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options – PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11204074/